


## 4th Quarter 2025 Report (October 1 - December 31)

Percent change evaluated relative to 4th Quarter 2024

### Summary

- As of January 2025, the Oregon PDMP includes Schedule V drugs and veterinarian-prescribed drugs.
- Overall PDMP prescriber enrollment has remained consistent compared to the 4<sup>th</sup> quarter of 2024 (Figure 1, Table 1).
- Gateway automated queries increased (+21.8%) while reports viewed decreased (-8.9%) following a 2024 activity spike. Web queries increased slightly (+1.7%). (Table 3)
- Total prescriptions increased 8.8%, largely due to the addition of Schedule V and veterinarian prescribed drugs. (Table 5).
- Stimulant prescriptions continue upward trends with amphetamine prescriptions increasing 8.7% and remaining the most prescribed drug and methylphenidate prescriptions increasing 11.5%.
- Pregabalin, newly included as a Schedule V drug in 2025, entered the top 10 prescribed list (Table 5).
- PDMP gateway integration use remained stable in both active facilities and active users.



- *Figure 1* shows the number of prescribers enrolled in the PDMP over time from 2013-2025. Registration has remained consistent since 2018.

**Table 1. Oregon Prescriber Enrollment and Use: October 1 - December 31, 2025.**

User Type	Prescribers <sup>1</sup>	Enrolled	Web Query	Automated Query	Total Query
All Prescribers (by DEA)	20,490	17,526 (85.5%)	1,148 (6.6%)	13,577 (77.5%)	13,669 (78.0%)
Top 4,000 Prescribers	4,000	3,918 (98.0%)	755 (19.3%)	3,563 (90.9%)	3,604 (92.0%)
Top 2,000 Prescribers	2,000	1,969 (98.5%)	494 (25.1%)	1,800 (91.4%)	1,823 (92.6%)

<sup>1</sup>Counts provided by unique DEA number. Providers may have multiple DEA numbers.

- Controlled substances were prescribed by 20,490 Oregon providers.
- During the 4th quarter, 78.0% of enrolled prescribers, 92.0% of the top 4,000 prescribers, and 92.6% of the top 2,000 prescribers submitted queries via the web portal and/or gateway.

- Query activity increased compared to Q4 2024, when 76.2% of enrolled prescribers submitted queries.

**Table 2. Special Requests: October 1 - December 31, 2025.**

Measure	Count
Patient Records	11
Healthcare Boards	39
Law Enforcement	8
<b>Total Special Requests</b>	<b>58</b>

- 58 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of requests.

**Table 3. PDMP Activity Summary Statistics: October 1 – December 31, 2025.**

User Type	Web Query	% Change <sup>1</sup>	Automated Queries	% Change <sup>1</sup>	Report Viewed	% Change <sup>1</sup>
Healthcare providers	77,137	1.7%	7,565,405	26.5%	900,959	6.2%
Pharmacies	55,169	-8.2%	1,519,165	2.8%	809,375	-21.3%
Delegates	174,387	5.2%	NA	NA	NA	NA
<b>Total<sup>2</sup></b>	<b>306,873</b>	<b>1.7%</b>	<b>9,084,570</b>	<b>21.8%</b>	<b>1,710,334</b>	<b>-8.9%</b>

<sup>1</sup>Percent change evaluated relative to same time period during the prior year.

<sup>2</sup>Query data drawn from Appriss AWA Rx E web portal, PMPi Gateway audit file and EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID, and date of query

- Web queries increased 1.7%, driven primarily by delegate users.
- Automated queries increased 21.8%, especially among healthcare providers, while integrated report viewing decreased 8.9% due to a return to baseline after elevated 2024 activity.

**Table 4. Activity for PDMP-Enrolled Providers: October 1 - December 31, 2025.**

Discipline	Total Accounts (by DEA)	% Change	Web Users	% Change	Integrated Users	% Change
MD/PA/DO	19,845	-7.5%	1,365	-5.0%	16,087	0.1%
NP/CNS-PP	5,645	-2.2%	1,205	1.2%	4,242	1.1%
RPh	3,886	5.1%	1,094	-11.6%	660	10.4%
Delegates	3,389	11.9%	1,866	5.4%	NA	NA
DDS/DMD	2,809	2.0%	288	-7.4%	335	2.1%
ND	787	14.2%	160	2.6%	520	10.6%

- Usage trends show an ongoing shift towards integrated gateway use and reduced reliance on the web portal.
- All provider groups increased integrated gateway usage, especially RPh (+10.4%) and ND (+10.6%) disciplines.

**Table 5. Top Prescriptions: October 1 - December 31, 2025.**


Drug	Number of Rx	% of all Rx	% Change
All	1,915,928	100%	8.8%
Amphetamine	264,570	13.8%	8.7%
Gabapentin	234,861	12.3%	-1.8%
Oxycodone	233,185	12.2%	-0.7%
Hydrocodone	188,152	9.8%	-4.7%
Methylphenidate	125,679	6.6%	11.5%
Lorazepam	81,619	4.3%	1.1%
Testosterone	76,028	4%	11.5%
Tramadol	70,800	3.7%	-2.3%
Pregabalin	66,227	3.5%	NA
Zolpidem	54,153	2.8%	-4.9%

- Controlled substance prescribing increased 8.8%, driven by the addition of schedule V and veterinarian-prescribed drugs.

- Stimulant prescribing continues to increase. Amphetamine (+8.7%) remains the most prescribed drug and methylphenidate prescriptions increased (11.5%).
- Gabapentin (-1.8%), oxycodone (-0.7%), and hydrocodone (-4.7%), prescriptions decreased.
- Pregabalin, a Schedule V drug, is newly reportable to the PDMP in 2025.

## Gateway Integration Trends


**Figure 2. Active facilities accessing Gateway integration: 2018-2025**



Oregon facilities only: Active status requires submission of at least one quarterly query, unique by facility ID.

- Facility participation in Gateway increased to 2,319 facilities.

**Figure 3. Active users accessing Gateway integration: 2018-2025**



Oregon users only: Active status requires submission of at least one quarterly query, unique by NPI or DEA number.

- The number of users submitting at least one query increased slightly to 24,621 users.

**Data Quality Monitoring**

In Oregon, the PDMP monitors all Schedule II-V prescriptions submitted by retail pharmacies. Pharmacies are responsible for submitting and correcting data issues, while the PDMP tracks errors and provides support as needed.

**Table 6. Prescription Errors: October 1 - December 31, 2025.**

Unique prescriptions flagged with an error	Quarterly Rejection Rate
5,300	0.28%

In Q4 2025, 5,300 prescriptions were flagged with an error, corresponding to a 0.28% rejection rate. Most flagged prescriptions contained non-fatal errors that did not affect upload.

**Contact: PDMP Research Analyst,**  
[pdmp.research@odhsosha.oregon.gov](mailto:pdmp.research@odhsosha.oregon.gov)